Abstract: The invention provides a method for treating substance abuse comprising administering an effective amount of olanzapine or pharmaceutically acceptable salt thereof to a patient in need thereof.
Type:
Grant
Filed:
November 25, 1997
Date of Patent:
December 12, 2000
Assignee:
Eli Lilly and Company
Inventors:
Charles M Beasley, Kurt Rasmussen, Gary D Tollefson
Abstract: The present invention discloses novel chimeric monoclonal antibodies, directed against proteoglycans of human melanoma cells, having antigen-specific variable regions of defined amino acid sequences. DNA constructs for the light and heavy chain variable regions comprising the novel antibodies of the invention are provided. Eukaryotic host cells capable of expression of the chimeric antibodies and comprising the novel chimeric antibody-encoding DNA constructs are also provided.
Type:
Grant
Filed:
July 31, 1989
Date of Patent:
December 3, 1996
Assignee:
Eli Lilly and Company
Inventors:
Lisa S. Beavers, Thomas F. Bumol, Robert A. Gadski
Abstract: Fermentation product A83543, comprising major components A83543A and A83543D and minor components A83543B, A83543C, A83543E, A983543F, A83543G, A83543H and A83543J, is produced by a newly described species, Saccharopolyspora spinosa. The A83543 components and their acid-addition salts (A83543 compounds) are useful as insecticides, particularly against Lepidoptera and Diptera species. Insecticidal, miticidal or ecto-parasiticidal combinations, compositions and methods are provided.
Type:
Grant
Filed:
March 17, 1995
Date of Patent:
March 5, 1996
Assignee:
DowElanco
Inventors:
LaVerne D. Boeck, Hang Chio, Tom E. Eaton, Otis W. Godfrey, Jr., Karl H. Michel, Walter M. Nakatsukasa, Raymond C. Yao
Abstract: Fermentation product A83543, comprising major components A83543A and A83543D and minor components A83543B, A83543C, A83543E, A983543F, A83543G, A83543H and A83543J, is produced by a newly described species, Saccharopolyspora spinosa. The A83543 components and their acid-addition salts (A83543 compounds) are useful as insecticides, particularly against Lepidoptera and Diptera species. Insecticidal, miticidal or ecto-parasiticidal combinations, compositions and methods are provided.
Type:
Grant
Filed:
October 10, 1991
Date of Patent:
November 8, 1994
Assignee:
DowElanco
Inventors:
LaVerne D. Boeck, Hang Chio, Tom E. Eaton, Otis W. Godfrey, Jr., Karl H. Michel, Walter M. Nakatsukasa, Raymond C. Yao
Abstract: New glycopeptide antibiotic A82846, comprising A82846A, A82846B and A82846C, is produced by Nocardia orientalis strains NRRL 18098, NRRL 18099 and NRRL 18100. The A82846 antibiotics have activity against Gram-positive bacteria comparable to that of vancomycin.
Type:
Grant
Filed:
May 9, 1990
Date of Patent:
May 17, 1994
Assignee:
Eli Lilly and Company
Inventors:
Robert L. Hamill, James A. Mabe, David F. Mahoney, Walter M. Nakatsukasa, Raymond C. Yao
Abstract: Newly discovered lipoglycopeptide antibiotic A84575 complex, comprising factors A, B, C, D, E, F, G, and H, is produced by submerged aerobic fermentation of a culture selected from Streptosporangeum carneum NRRL 18437, Streptosporangeum carneum NRRL 18505 or an A84575-producing mutant thereof. The antibiotics are active against Gram-positive bacteria.
Abstract: The present invention provides 3-(4-substitutedphenoxy)-3-phenyl propanamines capable of inhibiting the uptake of serotonin. These compounds are useful for treating many pharmacological disorders, including depression and obesity. These compounds can also be used to reduce the desire to smoke and consume alcohol.
Abstract: A novel antibiotic complex, A59770, individual factors and derivatives thereof, are provided. The A59770 compounds are useful as pesticides, particularly as rodenticides. Further provided are methods for reducing a rodent population, rodenticidal compositions, and an A59770-producing Amycolatopsis orientalis culture.
Type:
Grant
Filed:
April 11, 1990
Date of Patent:
August 24, 1993
Assignee:
Eli Lilly and Company
Inventors:
Marvin M. Hoehn, Karl H. Michel, Raymond C. Yao
Abstract: Newly-discovered antibiotic A10255 factors B, C, E, F, G, H, and J are produced by submerged aerobic fermentation of Streptomyces gardneri NRRL 15537 and NRRL 18260 or an A10255-producing variant or mutant thereof. The antibiotics are active against a wide variety of pathogenic bacteria, and also enhance feed-utilization efficiency in chickens, weanling pigs, cattle and sheep. The antibiotics can also be used to detect the thiostrepton-resistance gene in Streptomyces species.
Abstract: A method is provided for treating a susceptible neoplasm in mammals which comprises administering to a mammal in need of said treatment an effective amount for treating the neoplasm of the compound N-[[(4-chlorophenyl)amino]carbonyl]-1-butanesulfonamide or a pharmaceutically acceptable salt thereof, wherein said neoplasm is selected from the group consisting of ovarian, non-small cell lung, gastric, pancreatic, renal cell, breast, colorectal, small-cell lung, melanoma, head and neck, Kaposi's sarcoma, and rhabdomyosarcoma.
Abstract: New intermediates, and processes therefor, provide an efficient method for deriving 4-amino-1,2,-2a,3,4,5-hexahydrobenz[cd]indoles, which are themselves intermediates to useful CNS agents, from the Kornfeld-Woodward ketone and like compounds. Preferred embodiments provide means for the preparation of substantially pure enantiomers of the desired 4-amino-1,2,2a,3,4,5-hexahydrobenz[cd]indole.
Type:
Grant
Filed:
November 26, 1991
Date of Patent:
May 18, 1993
Assignee:
Eli Lilly and Company
Inventors:
Thomas J. Kress, M. Robert Leanna, Michael J. Martinelli, Barry C. Peterson
Abstract: Permeation enhancement compositions are disclosed. Said compositions include from 30 to 70 parts by weight ethanol, from 0.1 to 10 parts by weight azone, from 30 to 80 parts by weight water and optionally from 10 to 30 parts by weight propylene glycol, which compositions provide increased percutaneous absorption of a pharmacologically active agent disposed therewith.
Abstract: Novel substituted quinazolinones have been found to exhibit specific binding to cholecystokinin (CCK) receptors in the brain and/or peripheral site such as the pancreas and ileum. The quinazolinones are CCK receptor antagonists and find therapeutic application in the treatment of gastrointestinal disorders and central nervous system disorders, and are useful for appetite regulation in mammals. Pharmaceutical formulations for such indications are described.
Type:
Grant
Filed:
September 20, 1991
Date of Patent:
March 23, 1993
Assignee:
Eli Lilly and Company
Inventors:
Melvin J. Yu, Jefferson R. McCowan, K. Jeff Thrasher
Abstract: New glycopeptide antibiotic A83850, comprising A83850A, and A83850B, is produced by Amycolatopsis albus strain NRRL 18532. A83850A and A83850B can be reduced to give new biologically active derivatives. The A83850 antibiotics have activity against Gram-positive bacteria comparable to that of vancomycin.
Abstract: This invention provides the use of certain benzofuransulfonamide, benzothiophenesulfonamide, and indolesulfonamide derivatives in the treatment of susceptible neoplasms in mammals. Also provided are certain novel benzofuransulfonamide and benzothiophenesulfonamide derivatives and their pharmaceutical formulations.
Abstract: Three new groups of 9-N-substituted derivatives of erythromycylamine with superior oral activity against Gram-positive pathogens, new processes for preparing derivatives of erythromycylamine and aliphatic aldehydes by controlling the pH of the reaction and by catalytic hydrogenation, and pharmaceutical compositions and methods using the new compounds are provided.
Type:
Grant
Filed:
August 18, 1989
Date of Patent:
May 5, 1992
Assignee:
Eli Lilly and Company
Inventors:
Rosanne Bonjouklian, Manuel Debono, Herbert A. Kirst, Julie A. Wind
Abstract: Novel 12-membered lactone and 11-membered lactone derivatives of erythromycin, having antimicrobial activity against certain Gram-positive pathogens such as Steptococcus pyogenes and Gram-negative cocci such as Haemophilus influenzae, and useful as intermediates to other macrolide derivatives, are disclosed.
Abstract: New Polyether antibiotic A82810, its acyl and alkyl ester, acyl ester and urethane derivatives, and salts thereof, are useful antibacterial and anticoccidial agents and increase feed-utilization efficiency in animals. Methods of making A82810 by culture of Actinomodura fibrosa sp. nov. NRRL 18348 and synergistic compositions of the A82810 compounds with nicarbazin, 4,4'-dinitrocarbanilide, certain napthalenamine and benzenamine compounds and metichlorpindol are also provided.